This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and HMA-based combination therapies.

2021年5月6日 · This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and...

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA-approved for elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive chemotherapy. The primary objective of the current study was to impart our institutional experience with the above regimen, outlinin …

Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying progression to leukemia. However, a vast majority of patients will ...

2024年11月5日 · Patients with some MR mutations have been shown to benefit from venetoclax plus hypomethylating agents (VEN+HMA) regimen. VEN+HMA and intensive chemotherapy have been compared in AML patients overall, but has not been compared in the AML-MR subtype.

2025年2月18日 · 2022年发表了WHO第五版和国际共识标准 (ICC)两套AML 分类系统，两者均整合了新的分子学结果，并突出了生物学定义的和临床相关的AML 亚型。 本文讨论了两个系统之间的异同，以及自引入这些分类以来所面临的挑战和吸取的教训。 值得注意的是，急性早幼粒细胞白血病 (APL) 通常与PML::RARA易位相关，是一种独特的临床病理学 AML 疾病，占 AML 的5%-10%。 APL的初始治疗通常为全反式维甲酸 (ATRA) +三氧化二砷 (ATO)，WBC>10K/μL的患 …

2024年9月13日 · Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older …

对于有与mds一致的细胞遗传学改变（之前被归类为aml-mrc）且既往使用过去甲基化药物（hma）的aml患者，标准诱导治疗的获益与cpx-351/阿糖胞苷和柔红霉素双药脂质体包封治疗的获益无差异。

2024年6月6日 · 低甲基化药物（HMA）+维奈克拉（VEN）是老年或化疗不耐受的急性髓系白血病（AML）患者的标准治疗方法。 虽然VEN的说明书中推荐连续28天的治疗周期，但缩短VEN的治疗周期可能会减轻细胞减少症并提高耐受性。 目前尚不清楚较短的VEN周期与标准的HMA+VEN方案在疗效/安全性方面的比较结果。 方法. 我们在7个法国中心（n=82）进行了新诊断（ND）AML患者的回顾性比较，这些患者接受了阿扎胞苷（AZA）7天加VEN 7天（“7+7”方案）的治疗，并 …

2023年10月11日 · Venetoclax (VEN) in combination with a hypomethylating agent (HMA) (azacitidine or decitabine) has emerged as a promising treatment for frail AML patients who are 75 years of age or older, or...